Company intelligence / Profile preview

Novastra Therapeutics

Worcester, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Novastra Therapeutics is a preclinical-stage biotechnology company focused on developing RNA-based therapies for neurodegenerative diseases. The company was founded by leading researchers from the UMass Chan Medical School to translate breakthroughs in antisense oligonucleotides (ASOs) and RNA interference (RNAi) into clinical treatments. Their primary therapeutic targets include Amyotrophic Lateral Sclerosis (ALS) and Huntington's disease, utilizing a platform designed for efficient delivery to the central nervous system. Novastra aims to silence disease-causing genes to halt or reverse the progression of fatal neurological conditions.

Therapeutic areas: Neurology
Modalities: Antisense oligonucleotideSmall interfering RNARNA therapy
Industry: Biotech

Partnerships

UMass Chan Medical School

Beyond the preview

Go deeper on Novastra Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novastra Therapeutics.

Explore the full profile